IMPORTANT LEGAL NOTICE - The information on this site is subject to adisclaimerand acopyright notice
Contact   |   Search  
Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element
Cell factory - BAck to the homepage Graphic element Graphical element
Foreword Graphic element Graphical element
Introduction Graphical element
Index by Index by Area Index by Partners Index by Keywords Gr&phic element Graphical element
Volume 1 Graphical element
Graphical element Graphical element

New drugs and treatment strategies of urinary incontinence and voiding disorders



Cell factory area


EU Contribution

2 347 859 Euro


36 months


Research project

Starting date


kidney function
urinary incontinence
Graphical element

Graphical element
Graphical element

The overall goal is to establish a new therapeutic strategy for the treatment of urinary incontinence in elderly men and women, and to develop novel drugs for this purpose. This will be based on extensive basic science and clinical research of key G-protein coupled receptors and kidney function. Clinical studies will identify and characterise the large group of patients that will benefit from such a novel treatment principle.

As necessary new drugs will be developed for treatment of elderly incontinent patients. Exploitation of such drugs will allow efficient treatment and symptom relief for these very common life-disrupting disorders in elderly patients, improving health and life quality for a large proportion - estimated 30 million - of the rapidly-growing elderly population in the European Union.

Graphical element
Graphical element

No efficient treatment is available for half of the 30-40 million elderly patients in the EU suffering from urinary incontinence and nocturia. The goal is to establish a new efficient therapeutic strategy to improve health and life quality for patients with these disorders. For this purpose new short-acting drugs will be developed.

These objectives require integrated and comprehensive efforts:

  • Basic science to characterise kidney function at the molecular, cellular and integrated level regarding renal water and sodium excretion.
  • Clinical research to characterise patients that will benefit from a new therapeutic strategy.
  • Basic, clinical and pharmaceutical science to develop and characterise new drugs for treatment of elderly incontinence patients.

Graphical element
Graphical element

The project aims to provide a new therapeutic strategy and symptom relief, and to provide new drugs for this purpose, to efficiently treat the elderly suffering from urinary voiding disorders including incontinence and nocturia. To achieve this ten leading European research groups have established this multidisciplinary, integrated and interactive research programme. The partners include one leading pharmaceutical company, three leading clinical research groups, and six leading basic science groups in this area.

The following objectives will be pursued:

  • Obtain detailed knowledge of kidney function, the vasopressin system, and urinary tract function, in middle-aged and elderly human volunteers and patients.
  • Develop novel drugs with a short duration of action to treat patients with incontinence or nocturia. Lead compounds exist.
  • Characterise kidney function at the molecular, cellular and integrated level regarding water and sodium excretion. This will establish basic information of the system and provide systems to test at all levels novel lead compounds.
  • Lead compounds will be used in human volunteers and in initial clinical trials in patients.

Thus, through extensive basic and clinical research in kidney function at the molecular, cellular and integrated level, including volunteers and patients, the efforts aims at providing a new therapeutic strategy for these very large groups of patients.

Graphical element
Graphical element
  • Characterisation of kidney function at the molecular, cellular and integrated level regarding renal excretion of water and sodium. This will also be characterised in elderly volunteers and patients with incontinence or nocturia.
  • Characterise new short acting candidate drugs.
  • Complete initial clinical trials of the effect of the novel drugs in patients with incontinence.
  • Final support for the new therapeutic strategy of middle-aged and elderly patients.
  • Fulfil a detailed exploitation plan.

Graphical element
Graphical element
  Søren Nielsen
Department of Cell Biology
Institute of Anatomy
University of Aarhus
8000 Aarhus C, Denmark
Tel: +45 89423046
Fax: +45 86198664

  Robert Haigh
Ferring Research Ltd.
Chilworth Research Centre
1 Venture Road
S016 7NP Southhampton, United Kingdom
Tel: +44 2380763435
Fax: +44 2380763415

Joergen Froekiaer
Skejby Hospital
8200 Aarhus N, Denmark
Tel: +45 89495275
Fax: +45 89496012

Peter Deen
Department of Cell Physiology
University Medical Center Nijmegen
9101 NCMLS Research Tower
7th Floor, UMC St Radboud
6500 HB Nijmegen, The Netherlands
Tel: +31 243616413
Fax: +31 243617347

Walter Rosenthal
Forschungsinstitut fuer Molekulare Pharmakologie
Robert-Rossle-Str. 10
13125 Berlin, Germany
Tel: +49 3094793100
Fax: +49 3094793109

Stefan Hohmann
Dept. of Cell and Molecular Biology
Göteborg University
Medicinaregatan 9E
405 30 Göteborg, Sweden
Tel: +46 317732595
Fax: +46 317732599

Andreas Engel
M.E. Müller Institute for Microscopy
Structural Biology Biozentrum
Klingelbergstraße 70
4056 Basel, Switzerland
Tel: +41 612672261/62
Fax: +41 612672109

Helmut Grubmueller
Max-Planck-Institut fuer Biophysikalische Chemie
AG Theoretische Molekulare Biophysik
Am Fassberg 11
37077 Göttingen, Germany
Tel: +49 5512011763
Fax: +49 5512011089

Anders Mattiasson
Department of Urology
Lund University
Getingevägen 4
22185 Lund, Sweden
Tel: +46 46171179
Fax: +46 462112598

Paul Abrams
Dept. of Urology
Southmead Hospital
Southmead Road
BS10 5NB Bristol, United Kingdom
Tel: +44 1179595690
Fax: +44 1179502229
Graphical element